Bilastine 20MG + Montelukast 10MG Tablets is a combination oral solid dosage form comprising two active pharmaceutical ingredients present in a single-tablet format. In the development of a combination tablet, the characteristics of each active, excipients, blend properties, compression characteristics and stability of the finished product are all carefully considered. Should a pharmaceutical franchisee be looking to include Bilastine 20MG + Montelukast 10MG Tablets into a structured PCD Pharma Franchise product portfolio, this formulation can be referenced.
The formulation contains Bilastine 20MG + Montelukast 10MG plus appropriate pharmaceutical excipients. Depending on the specified formulation design, excipient systems can include one or more fillers, binders, disintegrants, lubricants, glidants or other functional components, with an emphasis on achieving consistency between batches.
Development of a bilastine and montelukast combination product begins by reviewing the compatibility of each active with its counter component and with the selected excipients. As combination formulations feature more than one active, maintaining a homogenous distribution of components is key during formulation development.
Fillers can assist with tablet weight adjustments, as well as processing handling. Binders help to create granules and promote tablet integrity, with disintegrants responsible for establishing the appropriate disaggregation profile of the batch. Lubricants and glidants can aid the tablet compression process itself.
The selected excipients need to be compatible with each of the component actives in storage and processing. Such compatibility can be studied preformulation by measuring physical properties, potential moisture sensitivity, flow and homogeneity characteristics and any interactions between the formulation components.
The formulation finalization occurs after further optimization of the bilastine to montelukast ratio, tablet weight and tablet compression parameters.
Accurate measurement of component actives ensures their proper distribution in manufacturing. Both raw materials are typically tested against their approved specifications before inclusion in the blend.
Particle size distribution can influence blend homogeneity and flow behavior during manufacturing, making optional material preselection by sieving or other processing desirable.
Both the active ingredients and excipients are generally incorporated in an established sequence using consistent mixing practices to achieve a uniform blend for each tab used. Blend uniformity testing at different blend points can confirm the homogeneity of each constituent within the blend, with is especially important for combination formulations.
Granulation parameters such as granuloid size, flow, moisture content and mixture homogeneity can be monitored when relevant. For direct compression formulations, powder parameters such as flow and compressibility are regularly measured before the material is sent to a tablet press.
The final bilastine and montelukast tablet set, following compression, is produced using a compression force, feed speed and tooling setup from the established range. Tablet hardness, weight variation, thickness and appearance are generally checked for consistency throughout production.
Tablets should demonstrate adequate mechanical strength against handling or transportation, and appropriate hardness to facilitate disintegration performance. Tablet surging is best avoided, with excessive strength potentially hindering the disintegration time of the finished product.
Assessment of tablet friability can help to identify treatment for excessive physicalabrasion resistance. Other visual components such as surface holding or capping are monitored to assess other mechanical stress points during processing. Adjustment of compression force is also conducted so as to be set within a defined production window.
Finished product specifications form the documented basis that confirms that Bilastine 20MG + Montelukast 10MG Tablets meet the final formulation design. Both the bilastine and montelukast component actives can be tested for identity and amount through validated analytical methods.
Common quality testing measures include weight variation, uniformity of dosage, flow properties, hardness, disintegration, friability and dissolution. Additional response substance or product-specific requirements are also considered. Analytical procedures should be able to measure the defined active two components both individually and together in the finished product.
Over time, stability samples are regularly monitored to assess the influence of storage conditions on a comprehensive panel of parameters including appearance, assay, dissolution, degradation, physicals and disaggregation. Stability data can inform appropriate shelf life duration, packaging and storage conditions for the finished product.
Packaging of Bilastine 20MG + Montelukast 10MG Tablets is, like other formulation development activities, carried out in adherence to strict product specifications and formulary guidelines. The package system must safeguard the product form factors from dust, moisture and potential contaminants.
Moldered packet, blister or strip packaging may be suitable when performance profiles are appropriate, and the final packaging concept is checked to ensure manufacturing seal quality and environmental exposure protection. The packaging material is qualified with regard to any potential chemical interactions with the formulation contents.
Product artwork exhibits the composition with any required regulatory information such as dosage, manufacturing batch, expiration period, basic product care information, batch number, product licensure or certification details and packaging specifications. Professional packaging and presentation can help augment product inventory across the PCD Pharma Franchise development.
Intended for pharmaceutical clienteles, the bilastine + montelukast combination product can be adopted into a wider range of oral solid-dose formats through externalizing identical processing specifications, transparent analyses, packaging procedures and quality assurance practices. Proper raw-material specifications, blend procedures, tablet compression best practices, and packaging standards aid in the leadership of quality control standards for the entire product array.
Such combination formulations can be incorporated into a diversification of PCD Pharma Franchise ranges through a holistic approach to standard operating procedures, documentation, quality assurance testing and product presentation standards.
Bilastine 20MG + Montelukast 10MG Tablets with formulation, manufacturing, quality control, stability, packaging and PCD Pharma Franchise details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech